Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program

The Defense Health Agency Aurora, through the TRICARE Management Activity, is soliciting quotes to support the Military Health System’s integrated pharmacy benefits program under solicitation number HT9402-26-Q-9202. This requirement, classified under NAICS 325412 Pharmaceutical Preparation Manufacturing and PSC 6505 DRUGS AND BIOLOGICALS, involves the procurement of pharmaceutical agents in accordance with 10 U.S.C. § 1074g. The Department of War Pharmacy and Therapeutics Committee will evaluate these agents based on clinical and cost effectiveness to determine their classification within the Uniform Formulary. Following these evaluations, the government may award Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements.

The scope of the upcoming May 2026 committee review includes several newly approved drugs and subclasses, specifically Cardamyst, Myqorzo, Ontralfy, Pivya, Sdamlo, Vybrique, and Zycubo. These agents span various therapeutic categories, including calcium channel blocking agents, cardiovascular agents, skeletal muscle relaxants, beta-lactam antibiotics, phosphodiesterase-5 inhibitors, and electrolyte-mineral-trace element replacements. Performance for these pharmaceutical programs is located in San Antonio, Texas.

The deadline for responses to this solicitation is March 26, 2026. A pre-quotation teleconference was scheduled for March 11, 2026, to discuss the instructions and requirements. Documentation for this opportunity includes 11 attachments, such as specific price lists for the drugs under review, clinical question response instructions, and the official Request for Quotation. Julianne Canaley serves as the point of contact for clinical question submissions and administrative inquiries.